Wikidata

(Q65341768)

English

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

clinical trial

In more languages
default for all languages
No label defined

No description defined

Statements

title
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer (English)
0 references
country
Australia
0 references
Austria
0 references
Belgium
0 references
Brazil
0 references
Canada
0 references
Denmark
0 references
France
0 references
Germany
0 references
Greece
0 references
Israel
0 references
Italy
0 references
Japan
0 references
Mexico
0 references
Netherlands
0 references
Poland
0 references
Portugal
0 references
Spain
0 references
Taiwan
0 references
Turkey
0 references
United Kingdom
0 references
start time
2 November 2015
0 references
end time
23 September 2019
0 references
number of participants
1,200
0 references
minimum age
18 year
0 references
maximum age
130 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q65341768&oldid=2236702242"